多发作精神分裂症维持治疗中标准剂量与减量抗精神病药的复发预防比较:随机对照试验的系统综述与荟萃分析
该系统综述与荟萃分析纳入22项研究(24个试验,3282例多发作精神分裂症或分裂情感障碍患者),比较低剂量(标准剂量下限的50-99%)和极低剂量(低于标准剂量下限的50%)与标准剂量抗精神病药维持治疗的复发及全因停药风险。极低剂量与低剂量之间无显著差异。结论提示维持治疗中抗精神病药剂量不宜低于急性稳定期的标准剂量范围。
核心结论
- 多发作精神分裂症维持治疗中,抗精神病药剂量低于标准剂量范围与复发及全因停药风险增加相关。
- 极低剂量与低剂量之间在复发和全因停药风险上无显著差异。
研究设计与样本
- 系统综述与荟萃分析,检索Embase、Medline、PsycINFO和Cochrane Library自建库至2020年6月17日的随机对照试验。
- 纳入标准为成年精神分裂症或分裂情感障碍患者、基线临床稳定、试验时长至少24周、比较同一抗精神病药至少两种剂量。
- 排除首发精神病或难治性精神分裂症试验;最终纳入22项研究,报告24个试验,共3282例受试者。
- 采用随机效应模型进行荟萃分析,二分类数据计算风险比(RR),连续数据计算Hedges' g。
关键数值与推荐
- 低剂量定义为标准剂量下限的50-99%,极低剂量定义为低于标准剂量下限的50%,标准剂量定义为高于国际共识研究推荐的治疗剂量下限。
- 主要结局为复发和全因停药;亚组分析(双盲与开放标签、第一代与第二代抗精神病药、口服与长效针剂)结果与总体一致。
临床怎么用
- 多发作精神分裂症维持治疗中,抗精神病药剂量不宜低于急性稳定期推荐的标准剂量范围下限。
- 减量至低剂量或极低剂量均与复发和全因停药风险增加相关,临床决策需权衡利弊。
局限性
- 多数研究在偏倚风险评估中被归类为存在一些担忧,主要因缺乏公开的研究注册。
- 研究间异质性在部分分析中较高(如极低剂量复发分析I²=70%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dose reduction of antipsychotic maintenance treatment in individuals with schizophrenia could be desirable to minimise adverse effects, but evidence for this strategy is unclear. We aimed to compare risks and benefits of reduced versus standard doses of antipsychotics. METHODS: We searched Embase, Medline, PsycINFO, and the Cochrane Library from database inception until June 17, 2020, for randomised trials in adults with schizophrenia or schizoaffective disorder lasting at least 24 weeks, including individuals clinically stable at baseline, and comparing at least two doses of the same antipsychotic, excluding trials in first-episode psychosis or treatment-resistant schizophrenia. We compared low-dose (within 50-99% of the lower limit of the standard dose) and very-low dose (less than 50% of the lower limit) with standard dose, defined as doses higher than the lower limit of the treatment dose recommended by the International Consensus Study. Data from published reports on number of participants, treatment, sex, age, number of events, and changes in psychopathology scores were extracted independently by at least two authors. Investigators or sponsors were contacted by email to obtain missing information regarding outcomes. Co-primary outcomes were relapse and all-cause discontinuation. Study-level data were meta-analysed using random-effects models, calculating risk ratios (RRs) for dichotomous data, and Hedges' g for continuous data. The protocol was registered with OSF registries. FINDINGS: 7853 references were identified in the database search and one additional reference from a manual review of relevant studies. 5744 abstracts were assessed for eligibility, and 101 references were assessed for full-text review. Of these, 79 were excluded for a variety of reasons, resulting in 22 studies being included in the meta-analysis, reporting on 24 trials and 3282 individuals. Study participants had a median age of 38 years (IQR 36-40) with 2166 (65·9%) males and 1116 (34·0%) females. Compared with standard dose, low dose increased the risk of relapse by 44% (16 trials, 1920 participants; RR 1·44, 95% CI 1·10-1·87; p=0·0076; I2=46%) and the risk of all-cause discontinuation by 12% (16 trials, 1932 participants; RR 1·12, 1·03-1·22; p=0·0085; I2=0%). Very low dose increased the risk of relapse by 72% (13 trials, 2058 participants; RR 1·72, 95% CI 1·29-2·29; p=0·0002; I2=70%) and all-cause discontinuation by 31% (11 trials, 1866 participants; RR 1·31, 1·11-1·54; p=0·0011; I2=63%). Compared with low dose, very low dose did not significantly increase the risk of relapse (five trials, 686 participants; RR 1·31, 95% CI 0·96-1·79; p=0·092; I2=51%) or all-cause discontinuation (five trials 686 participants; RR 1·11, 95% CI 0·95-1·30; p=0·18; I2=43%). Subgroup analyses comparing double-blind versus open-label studies, first-generation versus second-generation antipsychotics, and oral versus long-acting injectable antipsychotics were consistent with the overall results. Most studies were classified as having some concerns in the risk of bias assessment, which was mainly caused by absence of publicly available study registrations. INTERPRETATION: During maintenance treatment in multi-episode schizophrenia, antipsychotic doses should probably not be reduced below the standard dose range recommended for acute stabilisation, because reducing the dose further is associated with an increased risk of both relapse and all-cause discontinuation. FUNDING: None.
引用
- Højlund M, Kemp AF, Haddad PM, et al. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials. Lancet Psychiatry. 2021. PMID: 34023019. doi:10.1016/S2215-0366(21)00078-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。